MK-0646
Biological
Merck Sharp & Dohme Corporation
Total Payments
$242,631
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $122,667 | 1 | 0 |
| 2017 | $119,963 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $242,631 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase I, Randomized Phase II Study of Gemcitabine plus Erlotinib plus MK-0646, Gemcitabine plus MK-0646, and Gemcitabine plus Erlotinib for Patients with Advanced Pancreatic Cancer | Merck Sharp & Dohme Corporation | $242,631 | 0 |
Top Doctors Receiving Payments for MK-0646
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $242,631 | 3 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $242,631
Product Information
- Type Biological
- Total Payments $242,631
- Total Doctors 0
- Transactions 3
About MK-0646
MK-0646 is a biological associated with $242,631 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $122,667 was paid across 1 transactions to 0 doctors.
The most common payment nature for MK-0646 is "Unspecified" ($242,631, 100.0% of total).
MK-0646 is associated with 1 research study, including "A Phase I, Randomized Phase II Study of Gemcitabine plus Erlotinib plus MK-0646, Gemcitabine plus MK-0646, and Gemcitabine plus Erlotinib for Patients with Advanced Pancreatic Cancer" ($242,631).